Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study [5]

European Heart Journal

Volumn 27, Issue 12, 2006, Pages 1508-1509

  Dominguez, Jaime ^a   Kanna, Balavenkatesh ^a,b  

^a Lincoln Hospital   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONFOUNDING VARIABLE; CORONARY RISK; CORONARY STENT; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; LIFESTYLE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RECALL BIAS; SELF REPORT;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; TREATMENT OUTCOME;

EID: 33745725943     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl008     Document Type: Letter

References (5)

1. Montalescot G, Barragan P, Wittenberg O et al. Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005;26:2520-2523.
2. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
3. Clarke PM, Fiebig DG, Gerdtham UG. Optimal recall length in survey design. http://www.economics.adelaide.edu.au/workshops/doc/ optimalrecalllengthinsurveydesign.pdf.
4. Moles DR, dos Santos Silva I. Causes, associations and evaluating evidence; can we trust what we read? Evid Based Dent 2000;2:75-78.
5. Mamdani M, Sykora K, Li P, Normand ST et al. Reader's guide to critical appraisal of cohort studies: asessing potential for confounding. BMJ 2005;330:960-962.